- Top Workplaces
- Arcturus Therapeutics
Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine (Kostaive®) in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza.
Purpose
Building innovative RNA medicines
Vision
Our hope and vision is to build transformative, life-changing medicines for patients and their families.
Mission
Using company’s key proprietary technology to address the major hurdles in RNA development, namely the effective and safe delivery of RNA therapeutics to disease-relevant target tissues.
Values
- Respectful
- We value each other and their input and ideas, approach each other with kindness, treat others as wish to be treated. Disrespectful behavior is addressed and conflict is addressed in a positive manner.
Headquarters
San Diego, CA
Employees
201 US Employees
Industry
Biotechnology
We're Hiring!
Recent Awards
Company Snapshots
